drugset / Trial / NCT03747042
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Phase 2
Completed
61 enrolled
University of Texas Southwestern Medical Center
Cancer Prevention Research Institute of Texas · collab
NaSingle-groupOpen-labelTreatment
Summary
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with standard of care. They will then undergo definitive surgical resection of their primary tumor (mastectomy vs lumpectomy) as per standard of care guidelines.
Timeline
- Start
- 2018-11-27
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |